The authors regret an error in Table 4 stating that the primary outcome of total in-hospital symptomatic venous thromboembolic events occurred in 0.4% of patients receiving low-molecular-weight heparin. The correct symptomatic venous thromboembolism rate in low-molecular-weight heparin patients in this cohort was 1.4%, equal to the symptomatic venous thromboembolism rate in patients receiving direct oral anticoagulants, as was correctly reported in the text.
The authors would like to apologise for any inconvenience caused.
Article info
Identification
Copyright
© 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Direct Oral Anticoagulants Are a Potential Alternative to Low-Molecular-Weight Heparin for Thromboprophylaxis in Trauma Patients Sustaining Lower Extremity FracturesJournal of Surgical ResearchVol. 258
- PreviewTrauma patients are at a significant risk of venous thromboembolism (VTE), with lower extremity fractures (LEF) being independent risk factors. Use of direct oral anticoagusants (DOACs) for VTE prophylaxis is effective in elective orthopedic surgery, but currently not approved for trauma patients. The primary objective of this study was to compare the effectiveness and safety of thromboprophylaxis of DOACs with low-molecular-weight heparin (LMWH) in trauma patients sustaining LEF.
- Full-Text
- Preview
